Evidence map›Paper›PMID 34444660›Full record

ArticleNutrients2021

Anti-Obesity and Hypocholesterolemic Actions of Protamine-Derived Peptide RPR (Arg-Pro-Arg) and Protamine in High-Fat Diet-Induced C57BL/6J Mice.

Maihemuti Mijiti, Ryosuke Mori, Bingyu Huang, Kenichiro Tsukamoto, Keisuke Kiriyama, Keita Sutoh, Satoshi Nagaoka

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Untargeted metabolomics ofNutrition research and practice · 2025
    Article
  3. Article
  4. Article
  5. Anti-obesity peptides from food: Production, evaluation, sources, and commercialization.Comprehensive reviews in food science and food safety · 2025
    Review
  6. Article
  7. Review
  8. AJournal of pharmaceutical analysis · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maihemuti MijitiDepartment of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.
Ryosuke MoriDepartment of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.
Bingyu HuangDepartment of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.
Kenichiro TsukamotoDepartment of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.
Keisuke KiriyamaFordays Co., Ltd., Tokyo 103-0016, Japan.
Keita SutohFordays Co., Ltd., Tokyo 103-0016, Japan.
Satoshi NagaokaDepartment of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan.ORCID 0000-0002-5348-3187
Gifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dietary protamine can ameliorate hyperlipidemia; however, the protamine-derived active peptide and its hypolipidemic mechanism of action are unclear. Here, we report the discovery of a novel anti-obesity and hypocholesterolemic peptide, RPR (Arg-Pro-Arg), derived from protamine in mice fed a high-fat diet for 50 days. Serum cholesterol levels were significantly lower in the protamine and RPR groups than in the control group. White adipose tissue weight was significantly decreased in the protamine and RPR groups. The fecal excretion of cholesterol and bile acid was significantly higher in the protamine and RPR groups than in the control group. We also observed a significant decrease in the expression of hepatic SCD1, SREBP1, and adipocyte FAS mRNA, and significantly increased expression of hepatic PPARα and adipocyte PPARγ1 mRNA in the protamine group. These findings demonstrate that the anti-obesity effects of protamine are linked to the upregulation of adipocyte PPARγ1 and hepatic PPARα and the downregulation of hepatic SCD1 via SREBP1 and adipocyte FAS. RPR derived from protamine has a crucial role in the anti-obesity action of protamine by evaluating the effective dose of adipose tissue weight loss.

Indexed as

Adipose Tissue, WhiteAdiposityAnimalsAnticholesteremic AgentsAnti-Obesity AgentsBiomarkersCholesterolDiet, High-FatDisease Models, AnimalFatty Acid Synthase, Type ILiverMaleMiceMice, Inbred C57BLObesityOligopeptidesAnticholesteremic AgentsAnti-Obesity AgentsBiomarkersCholesterolFasn protein, mouseFatty Acid Synthase, Type IOligopeptidesPPAR alphaPpara protein, mousePPAR gammaPparg protein, mouseProtaminesScd1 protein, mouseSrebf1 protein, mouseStearoyl-CoA DesaturaseSterol Regulatory Element Binding Protein 1cholesterolfatobesitypeptideprotamineRPR

Identifiers

PMID34444660
PMCPMC8398848
OpenAlexW3184311036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.